ARCHIVES

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

This article is from The Cancer Letter archive.

Vol. 34 No. 08 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

Study Suggests Biomarker For Resistance to Tamoxifen

March 25, 2011

Obit: John Ultmann, A Leader In Clinical Oncology.

October 27, 2000

Center Leaders Ok Consortium Center Guidelines, Go Along With Most Core Grant Changes Backed By NCI

April 19, 1985

Broder Appointment Official; Will Keep Retroviral Laboratory, Will Not Serve as NCI Clinical Director

January 6, 1989

NCI To Invite Unaffiliated Oncologists To Enroll Patients On Phase III Trials

May 10, 2002

Mouse Strains For Retrovirus Research Available From NCU

March 23, 1984